Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
URB-597
Cat. No.:
0225LY-0502
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
URB-597 is a highly effective FAAH inhibitor (IC50 = 4.6 nM) that demonstrates oral bioavailability and does not interact with other targets related to cannabinoids.
Synonym:
KDS-4103; FAAH Inhibitor II; 546141-08-6; 3'-Carbamoyl-[1,1'-biphenyl]-3-yl cyclohexylcarbamate; [3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate; 3'-Carbamoylbiphenyl-3-yl cyclohexylcarbamate
CAS No.:
546141-08-6
Compound CID:
1383884
Formula:
C20H22N2O3
Formula Weight:
338.4
Specification
Targets&IC50:
FAAH: 4.6 nM
Relative Density:
1.23 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
URB-597 can be used in neuropharmacology to investigate the regulation of endocannabinoid levels through fatty acid amide hydrolase inhibition.
Library Information
Target:
FAAH
Receptor:
FAAH
Pathways:
Neuronal signaling; Autophagy; Metabolism
Plate Number:
AOCL-7
Plate Location:
e4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
245 mg/mL; 724 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
5 mg/mL; 14.78 mM
ALogP:
3.972
HBA_Count:
3
HBD_Count:
2
Rotatable Bond:
5
